Hologic Inc. Forecasted to Post Q1 2017 Earnings of $0.51 Per Share (HOLX)
Hologic Inc. (NASDAQ:HOLX) – Leerink Swann issued their Q1 2017 EPS estimates for Hologic in a research note issued to investors on Thursday. Leerink Swann analyst R. Newitter forecasts that the firm will post earnings per share of $0.51 for the quarter. Leerink Swann currently has a “Outperform” rating and a $46.00 price objective on the stock. Leerink Swann also issued estimates for Hologic’s Q2 2017 earnings at $0.53 EPS, Q3 2017 earnings at $0.55 EPS, Q4 2017 earnings at $0.56 EPS, FY2018 earnings at $2.37 EPS and FY2019 earnings at $2.66 EPS.
Hologic (NASDAQ:HOLX) last issued its quarterly earnings results on Wednesday, July 27th. The company reported $0.51 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.48 by $0.03. The company had revenue of $717.40 million for the quarter, compared to the consensus estimate of $703.66 million. Hologic had a return on equity of 26.25% and a net margin of 9.39%. The company’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.43 EPS.
A number of other research analysts also recently issued reports on the company. Piper Jaffray Cos. set a $40.00 price objective on Hologic and gave the company a “hold” rating in a research note on Monday, July 25th. They noted that the move was a valuation call. Barclays PLC raised Hologic from an “equal weight” rating to an “overweight” rating and boosted their target price for the company from $42.00 to $44.00 in a research report on Friday, September 23rd. Evercore ISI raised Hologic from a “hold” rating to a “buy” rating and boosted their target price for the company from $38.00 to $42.00 in a research report on Thursday, July 28th. Canaccord Genuity set a $45.00 target price on Hologic and gave the company a “buy” rating in a research report on Thursday, July 28th. Finally, Jefferies Group boosted their target price on Hologic from $42.00 to $43.00 and gave the company a “buy” rating in a research report on Thursday, July 28th. Six analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $42.71.
Hologic (NASDAQ:HOLX) opened at 38.88 on Monday. The firm has a 50-day moving average price of $38.33 and a 200 day moving average price of $36.10. Hologic has a 12 month low of $31.84 and a 12 month high of $41.66. The company has a market capitalization of $10.79 billion, a P/E ratio of 42.87 and a beta of 1.00.
In other news, Director Nancy Leaming sold 8,179 shares of the company’s stock in a transaction that occurred on Thursday, July 21st. The stock was sold at an average price of $37.00, for a total value of $302,623.00. Following the completion of the transaction, the director now directly owns 67,140 shares of the company’s stock, valued at $2,484,180. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.84% of the stock is owned by insiders.
Institutional investors have recently added to or reduced their stakes in the stock. Glenmede Trust Co. NA raised its position in Hologic by 259.8% in the first quarter. Glenmede Trust Co. NA now owns 18,710 shares of the company’s stock valued at $644,000 after buying an additional 13,510 shares in the last quarter. Ngam Advisors L.P. raised its position in Hologic by 11.7% in the first quarter. Ngam Advisors L.P. now owns 134,353 shares of the company’s stock valued at $4,636,000 after buying an additional 14,115 shares in the last quarter. Prudential Financial Inc. raised its position in Hologic by 20.3% in the first quarter. Prudential Financial Inc. now owns 2,627,461 shares of the company’s stock valued at $90,648,000 after buying an additional 444,115 shares in the last quarter. BlackRock Japan Co. Ltd raised its position in Hologic by 3.1% in the first quarter. BlackRock Japan Co. Ltd now owns 313,303 shares of the company’s stock valued at $10,809,000 after buying an additional 9,312 shares in the last quarter. Finally, Marietta Investment Partners LLC acquired a new position in Hologic during the first quarter valued at about $795,000. 94.51% of the stock is owned by institutional investors.
Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. Its Diagnostics products include its Aptima family of assays, which run on its advanced instrumentation systems (Panther and Tigris); ThinPrep system; the Rapid Fetal Fibronectin Test, and Procleix blood screening assays.
Receive News & Stock Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related stocks with our FREE daily email newsletter.